Gan&Lee doses first participant in GZC8072 Phase 1 study
Gan&Lee Pharmaceuticals announced the first participant has been dosed in a First-In-Human Phase 1 study of GZC8072 tablets, a novel ultra-long-acting once-weekly oral peptide GLP-1 RA.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.